Ainult tellijatele

Autor: Violetta Riidas • 28. veebruar 2011

Ainult tellijatele

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

Using aspirin for coronary heart prevention is less costly and more effective than doing nothing in men older than 45 with more than 10 percent 10-year-risk of the disease, according to a study by researchers at RTI International, University of Michigan, and University of North Carolina at Chapel Hill.

The study, published online in the Archives of Internal Medicine, used a Markov model to compare the costs and outcomes of prescribing low-dose aspirin alone, aspirin plus a proton-pump inhibitor, or no treatment for coronary heart prevention. The researchers specifically considered the effects of each treatment on cardiovascular events and risk of upper gastrointestinal bleeding.